Kari Strøno Wagner-Larsen

Kari Strøno Wagner-Larsen

Auto-generated profile, based on publicly available information

Kari Strøno Wagner-Larsen

Mohn Medical Imaging and Visualization Centre (MMIV), Department of Radiology, Haukeland University Hospital, Bergen, Norway

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
EHErlend Hodneland
Erlend Hodneland
SKSatheshkumar Kaliyugarasan
Satheshkumar Kaliyugarasan
KWKari Strøno Wagner-Larsen
Kari Strøno Wagner-Larsen
NLNjål Lura
Njål Lura
EAErling Andersen
Erling Andersen
IHIngfrid Salvesen Haldorsen
Ingfrid Salvesen Haldorsen
Uterine cervical cancer (CC) is the most common gynecologic malignancy worldwide. Whole-volume radiomic profiling from pelvic MRI may yield prognostic markers for tailoring treatment in CC. However, radiomic profiling relies on manual tumor segmentation which is unfeasible in the clinic. We present a fully automatic method for the 3D segmentation of primary CC lesions using state-of-the-art deep learning (DL) techniques. In 131 CC patients, the primary tumor was manually segmented on T2-weighted MRI by two radiologists (R1, R2). Patients were separated into a train/validation (n = 105) and a test- (n = 26) cohort. The segmentation performance of the DL algorithm compared with R1/R2 was assessed with Dice coefficients (DSCs) and Hausdorff distances (HDs) in the test cohort. The trained DL network retrieved whole-volume tumor segmentations yielding median DSCs of 0.60 and 0.58 for DL compared with R1 (DL-R1) and R2 (DL-R2), respectively, whereas DSC for R1-R2 was 0.78. Agreement for primary tumor volumes was excellent between raters (R1-R2: intraclass correlation coefficient (ICC) = 0.93), but lower for the DL algorithm and the raters (DL-R1: ICC = 0.43; DL-R2: ICC = 0.44). The developed DL algorithm enables the automated estimation of tumor size and primary CC tumor segmentation. However, segmentation agreement between raters is better than that between DL algorithm and raters.

22 January 2025 in BMC Cancer
Verified
Journal Article
Open access
PDF file
KWKari S. Wagner-Larsen
Kari S. Wagner-Larsen
NLNjål Lura
Njål Lura
AGAnkush Gulati
Ankush Gulati
SRStian Ryste
Stian Ryste
EHErlend Hodneland
Erlend Hodneland
IHIngfrid Salvesen Haldorsen
Ingfrid Salvesen Haldorsen
Background: Effective diagnostic tools for prompt identification of high-risk locally advanced cervical cancer (LACC) patients are needed to facilitate early, individualized treatment. The aim of this work was to assess temporal changes in tumor radiomics (delta radiomics) from T2-weighted imaging (T2WI) during concurrent chemoradiotherapy (CCRT) in LACC patients, and their association with progression-free survival (PFS). Furthermore, to develop, validate, and compare delta- and pretreatment radiomic signatures for prognostic modeling. Methods: A total of 110 LACC patients undergoing CCRT with MRI at baseline and mid-treatment were divided into training (cohortT: n = 73) and validation (cohortV: n = 37) cohorts. Radiomic features were extracted from tumors segmented on pre-CCRT and mid-CCRT T2WI and radiomic deltas (delta features) were computed. Two radiomic signatures for predicting PFS were constructed by least absolute shrinkage and selection operator (LASSO) Cox regression: Deltarad (from delta features) and Pre-CCRTrad (from pre-CCRT features). Prognostic performance of the radiomic signatures, 2018 International Federation of Gynecology and Obstetrics (FIGO) stage (I–IV), and baseline MRI-derived maximum tumor diameter (Tumormax: ≤2 cm; >2 and ≤ 4 cm; >4 cm) was evaluated by area under time-dependent receiver operating characteristics (tdROC) curves (AUC) in cohortT and cohortV (AUCT/AUCV). Mann–Whitney U tests assessed differences in radiomic delta features. PFS was evaluated using the Kaplan–Meier method with log-rank tests. Results: Deltarad (AUCT/AUCV: 0.74/0.79) marginally outperformed Pre-CCRTrad (0.72/0.75) for predicting 5-year PFS, and both signatures clearly surpassed that of FIGO (0.61/0.61) and Tumormax (0.58/0.65). In total, four features within Deltarad and Pre-CCRTrad significantly differed in delta feature values between progressors and non-progressors, being consistently lower in progressors (p ≤ 0.03 for all). High Deltarad and Pre-CCRTrad radiomic scores were associated with poor PFS (p ≤ 0.04 for Deltarad in cohortT/Pre-CCRTrad in both cohorts; p = 0.11 for Deltarad in cohortV). Conclusions: Delta- and pretreatment radiomic signatures equally allow early prognostication in LACC, outperforming FIGO stage and MRI-assessed maximum tumor diameter.

24 March 2022 in European Radiology
Verified
Journal Article
Open access
PDF file
KWKari S. Wagner-Larsen
Kari S. Wagner-Larsen
NLNjål Lura
Njål Lura
ØSØyvind Salvesen
Øyvind Salvesen
MHMari Kyllesø Halle
Mari Kyllesø Halle
DFDavid Forsse
David Forsse
IHIngfrid S. Haldorsen
Ingfrid S. Haldorsen
Objectives: To evaluate the interobserver agreement for MRI–based 2018 International Federation of Gynecology and Obstetrics (FIGO) staging parameters in patients with cervical cancer and assess the prognostic value of these MRI parameters in relation to other clinicopathological markers. Methods: This retrospective study included 416 women with histologically confirmed cervical cancer who underwent pretreatment pelvic MRI from May 2002 to December 2017. Three radiologists independently recorded MRI–derived staging parameters incorporated in the 2018 FIGO staging system. Kappa coefficients (κ) for interobserver agreement were calculated. The predictive and prognostic values of the MRI parameters were explored using ROC analyses and Kaplan–Meier with log-rank tests, and analyzed in relation to clinicopathological patient characteristics. Results: Overall agreement was substantial for the staging parameters: tumor size > 2 cm (κ = 0.80), tumor size > 4 cm (κ = 0.76), tumor size categories (≤ 2 cm; > 2 and ≤ 4 cm; > 4 cm) (κ = 0.78), parametrial invasion (κ = 0.63), vaginal invasion (κ = 0.61), and enlarged lymph nodes (κ = 0.63). Higher MRI–derived tumor size category (≤ 2 cm; > 2 and ≤ 4 cm; > 4 cm) was associated with a stepwise reduction in survival (p ≤ 0.001 for all). Tumor size > 4 cm and parametrial invasion at MRI were associated with aggressive clinicopathological features, and the incorporation of these MRI–based staging parameters improved risk stratification when compared to corresponding clinical assessments alone. Conclusion: The interobserver agreement for central MRI–derived 2018 FIGO staging parameters was substantial. MRI improved the identification of patients with aggressive clinicopathological features and poor survival, demonstrating the potential impact of MRI enabling better prognostication and treatment tailoring in cervical cancer. Key Points: • The overall interobserver agreement was substantial (κ values 0.61–0.80) for central MRI staging parameters in the 2018 FIGO system. • Higher MRI–derived tumor size category was linked to a stepwise reduction in survival (p ≤ 0.001 for all). • MRI–derived tumor size > 4 cm and parametrial invasion were associated with aggressive clinicopathological features, and the incorporation of these MRI–derived staging parameters improved risk stratification when compared to clinical assessments alone.

16 October 2023 in Cancer Medicine
Verified
Journal Article
Open access
KWKari S. Wagner‐Larsen
Kari S. Wagner‐Larsen
EHErlend Hodneland
Erlend Hodneland
KFKristine E. Fasmer
Kristine E. Fasmer
NLNjål Lura
Njål Lura
KWKathrine Woie
Kathrine Woie
IHIngfrid Salvesen Haldorsen
Ingfrid Salvesen Haldorsen
Background: Accurate pretherapeutic prognostication is important for tailoring treatment in cervical cancer (CC).Purpose: To investigate whether pretreatment MRI‐based radiomic signatures predict disease‐specific survival (DSS) in CC.Study Type: Retrospective.Population: CC patients (n = 133) allocated into training(T) (nT = 89)/validation(V) (nV = 44) cohorts.Field Strength/Sequence: T2‐weighted imaging (T2WI) and diffusion‐weighted imaging (DWI) at 1.5T or 3.0T.Assessment: Radiomic features from segmented tumors were extracted from T2WI and DWI (high b‐value DWI and apparent diffusion coefficient (ADC) maps).Statistical Tests: Radiomic signatures for prediction of DSS from T2WI (T2rad) and T2WI with DWI (T2 + DWIrad) were constructed by least absolute shrinkage and selection operator (LASSO) Cox regression. Area under time‐dependent receiver operating characteristics curves (AUC) were used to evaluate and compare the prognostic performance of the radiomic signatures, MRI‐derived maximum tumor size ≤/> 4 cm (MAXsize), and 2018 International Federation of Gynecology and Obstetrics (FIGO) stage (I–II/III–IV). Survival was analyzed using Cox model estimating hazard ratios (HR) and Kaplan–Meier method with log‐rank tests.Results: The radiomic signatures T2rad and T2 + DWIrad yielded AUCT/AUCV of 0.80/0.62 and 0.81/0.75, respectively, for predicting 5‐year DSS. Both signatures yielded better or equal prognostic performance to that of MAXsize (AUCT/AUCV: 0.69/0.65) and FIGO (AUCT/AUCV: 0.77/0.64) and were significant predictors of DSS after adjusting for FIGO (HRT/HRV for T2rad: 4.0/2.5 and T2 + DWIrad: 4.8/2.1). Adding T2rad and T2 + DWIrad to FIGO significantly improved DSS prediction compared to FIGO alone in cohort(T) (AUCT 0.86 and 0.88 vs. 0.77), and FIGO with T2 + DWIrad tended to the same in cohort(V) (AUCV 0.75 vs. 0.64, p = 0.07). High radiomic score for T2 + DWIrad was significantly associated with reduced DSS in both cohorts.Data Conclusion: Radiomic signatures from T2WI and T2WI with DWI may provide added value for pretreatment risk assessment and for guiding tailored treatment strategies in CC.

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
MHMari K Halle
Mari K Halle
EHErlend Hodneland
Erlend Hodneland
EHErling Andre Hoivik
Erling Andre Hoivik
KWKari Wagner-Larsen
Kari Wagner-Larsen
NLNjål Lura
Njål Lura
KWKathrine Woie
Kathrine Woie
Magnetic resonance imaging (MRI) has emerged as an important part of the diagnostic work-up in cervical cancer, with tumor volume and extent as important prognosticators. MRI radiomic tumor features may aid in prognostication and tailoring of treatment in cervical cancer. We extracted whole-volume radiomic texture features from 124 manually segmented tumors and performed unsupervised clustering yielding two distinct clusters. Overlapping clinicopathologic, genomic (whole exome sequencing, n=61), transcriptomic (L1000 arrays, n= 65) and molecular biomarker (n=82) data were applied to characterize the clusters. Independent of tumor size parameters, patients in cluster II had significantly reduced disease-specific survival as compared to those in cluster I (p>0.001), also within squamous cell carcinomas (n=96, p<0.001). Cluster II associated with high age (p=0.02), high FIGO-2009 stage (p<0.001), high BMI (p=0.03) and PR negative tumors (p=0.004). Distinct mutational and copy-number profiles were detected for the two clusters. By gene set enrichment analyses, gene sets associated to immune activation were enriched in cluster I tumors, whilst gene sets associated with oxidative phosphorylation and epithelial to mesenchymal transition associated to cluster II tumors. This study links radiomic signatures to distinct genomic profiles that may potentially aid in prognostication and tailoring of treatments in cervical cancer patients. Citation Format: Mari Kyllesø Halle, Erlend Hodneland, Erling Hoivik, Kari Wagner-Larsen, Njål G. Lura, Julie Dybvik, David Forsse, Bjørn I. Bertelsen, Camilla Krakstad, Ingfrid S. Haldorsen, Olivera Bozickovic, Kathrine Woie. Radiomic profiles revealing targets for therapy in cervical cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 513.